Board of Directors

Ken Anderson, M.D. is a co-founder and has served as a member of our Board since December 2015. Dr. Anderson has also served as the Kraft Family Professor of Medicine at Harvard Medical School since 2002, as well as Director of the Jerome Lipper Multiple Myeloma Center and Lebow Institute for Myeloma Therapeutics at Dana-Farber Cancer Institute since 2000 and 2007, respectively. Dr. Anderson is a member of the Institute of Medicine of the National Academy of Sciences and served as President of the International Myeloma Society from 2011 until 2015. Dr. Anderson serves on the following boards of directors: Window Therapeutics, a biotechnology company developing therapies that advance treatment options for patients with cancer and other serious diseases, since January 2021; Dynamic Cell Therapies, Inc. (formerly Raqia Therapeutics, Inc.), a CAR-T cell therapies company for cancer and other diseases, since September 2020; and Starton Therapeutics, Inc., a biotechnology company focused on blood cancer treatments, since September 2020. Dr. Anderson holds an M.D. from Johns Hopkins Medical School, where he also trained in internal medicine, and completed hematology, medical oncology and tumor immunology training at Dana-Farber Cancer Institute.

Laura Bessen, M.D., has served as a member of our Board of Directors since August 2022. Dr. Bessen currently serves as managing partner at Maxsam Advisors where she provides strategic clinical and medical affairs advice to clients across the biotechnology and pharmaceutical industries. Previously, she held roles of increasing responsibility over a 15-year career at Bristol Myers Squibb (BMS), most recently as Vice President, Head of US Medical. During her tenure at BMS, she helped launch 11 new products including Opdivo®, Yervoy®, Empliciti®, and Eliquis® and co-led BMS’ partnership with Gilead to develop Atripla®. Dr. Bessen also co-led the development of a BMS product commercialization model, life cycle management and launch investment principles. Earlier in her career, Dr. Bessen served in medical affairs roles at DuPont Pharmaceuticals. She currently serves on the board of directors of Artiva Biotherapeutics, an oncology company developing and advancing off-the-shelf, allogeneic natural killer cell therapies for patients with hematologic cancers or solid tumors, a role she has held since March 2022. Dr. Bessen received her M.D. degree from New York University School of Medicine and a B.S. in biochemistry from the State University of New York at Binghamton.

Bruce Downey, J.D. has served as a member of our Board of Directors since December 2015 and previously served as Chairman from June 2022 to June 2024. Previously, Bruce was Chairman and Chief Executive Officer of Barr Pharmaceuticals, a global generic pharmaceutical manufacturer, until its acquisition by Teva Pharmaceuticals in 2008. He has served on a part-time basis as an Advisory Partner of NewSpring Health Capital II, L.P., a venture capital firm, since April 2009. Prior to Barr Pharmaceuticals, Bruce was a practicing attorney for 20 years, working in both the private sector and for the federal government, including the U.S. Department of Justice and the U.S. Department of Energy. In addition, he serves on the boards of directors of OncoPep, a biotechnology company, and Cardinal Health, a healthcare services company, since April 2011 and July 2009, respectively. Bruce previously served on the boards of directors of Melinta Therapeutics, a biopharmaceutical firm, and Momenta Pharmaceuticals, a biotechnology company acquired by Johnson & Johnson. He holds a J.D. from Ohio State University and a B.S. in economics from Miami University.

Stephen (Steve) Fawell, Ph.D. has served as a member of our Board of Directors since September 2024. Stephen has nearly 35 years of drug discovery experience at global pharmaceutical companies focused on designing innovative molecules spanning oncology, virology and other disease areas. He has successfully advanced multiple investigational drugs into clinical trials which ultimately achieved regulatory approval. Most recently, he spent more than a decade at AstraZeneca as vice president, head of oncology small molecule drug discovery where he successfully transitioned more than 25 new drugs into the clinic; advanced camizestrant, ceralasertib and saruparib into late-stage development; and supported the development or approval of Tagrisso®, Lynparza®, Calquence® and Truqap®. At AstraZeneca, Stephen helped build the company’s targeted protein degradation platform. Earlier in his career, Stephen served as vice president, worldwide franchise discovery head, oncology at Merck where he was responsible for all preclinical efforts for the oncology franchise and managing global discovery collaborations. He previously served as executive director, drug discovery head, oncology at Novartis Institutes for Biomedical Research. Stephen holds a Doctor of Philosophy in biochemistry from University of Leeds and a Bachelor of Science in applied biology from University of Bradford.

Donna Grogan, M.D., has served as a member of our Board of Directors since August 2022. Dr. Grogan currently serves as Principal of Grogan Consulting where she supports clients across drug development, regulatory strategy, trial design and data interpretation. Between September 2013 and June 2019, Dr. Grogan served as Chief Medical Officer of Clementia Pharmaceuticals, which was acquired by Ipsen in April 2019. She previously served as Chief Medical Officer for several HealthCare Ventures portfolio companies including Anexon, Apofore and DecImmune. Between February 2007 and August 2011, Dr. Grogan served as Chief Medical Officer, Senior Vice President Clinical Development at FoldRx Pharmaceuticals, which was acquired by Pfizer in October 2010. Earlier in her career, she held roles of increasing responsibility at Sepracor Inc. where she was involved in multiple high-profile product approvals including Lunesta®, Xopenex HFA® and Brovana®. Dr. Grogan previously served as a board member, including membership on the Compensation Committee and the Scientific Committee, of Momenta Pharmaceuticals until it was acquired by Johnson & Johnson in October 2020. She holds an M.D. from University of Illinois College of Medicine and a B.A. from the College of the Holy Cross.

Andrew Hirsch, MBA joined C4 Therapeutics in September 2020 and serves as our President, Chief Executive Officer, and a member of our Board of Directors. Previously, Andrew was Chief Financial Officer and Head of Corporate Development at Agios Pharmaceuticals. Andrew has more than 25 years of experience in a range of strategic and operating roles in the biotechnology sector, including having previously served as President and Chief Executive Officer of BIND Therapeutics (BIND). Prior to being named President and Chief Executive Officer of C4 Therapeutics, Andrew held several other leadership positions at BIND, including Chief Operating Officer and Chief Financial Officer. Before joining BIND, Andrew was Chief Financial Officer at Avila Therapeutics from June 2011 until its acquisition by Celgene. From 2002 to 2011, Andrew held roles of increasing responsibility at Biogen, including Vice President of Corporate Strategy and M&A and Program Executive for the Tecfidera development team. Since May 2017, Andrew has served on the Board of Directors of Editas Medicine. Andrew holds an MBA from the Tuck School at Dartmouth College and a B.A. in economics from the University of Pennsylvania.

Steve Hoerter has served as a member of our Board of Directors since November 2024. Mr. Hoerter most recently served as the president and chief executive officer of Deciphera Pharmaceuticals, which was acquired by ONO Pharmaceutical for $2.4 billion in June 2024. He transformed Deciphera from a clinical-stage company into a fully integrated global organization with the successful approval and launch of QINLOCK^® for the treatment of advanced gastrointestinal stromal tumors in the U.S. and Europe, while advancing the company’s pipeline of novel product candidates. Prior to Deciphera, he was chief commercial officer of Agios Pharmaceuticals, where he launched the company’s first two approved products in the U.S., TIBSOVO® and IDHIFA®, both for the treatment of acute myeloid leukemia. Earlier in his career, he served as chief commercial officer of Clovis Oncology and held general management and commercial roles at Roche, Genentech, Chiron Corporation (acquired by Novartis) and Eli Lilly and Company. Mr. Hoerter is on the Board of Directors of ORIC Pharmaceuticals, a clinical-stage oncology company, and has previously served on the Boards of Constellation Pharmaceuticals (acquired by MorphoSys), Deciphera Pharmaceuticals and Ignyta (acquired by Roche). He earned his B.A. from Bucknell University, his MBA from Tilburg University in the Netherlands and an M.S. in management from the Krannert School of Management at Purdue University.

Owen Hughes has served as a member of our Board of Directors since November 2023. Mr. Hughes currently serves as chief executive officer of XOMA Corporation, a biotech royalty aggregator, where he also serves as a member of the Board of Directors. He previously served as co-founder and chief executive officer of Cullinan Oncology, where he led the development of the company’s portfolio of oncology assets through proof-of-concept. Under Mr. Hughes’s leadership, Cullinan raised over $400 million in capital through its initial public offering and advanced several assets into the clinic. Mr. Hughes also served as chief business officer of Intarcia Therapeutics, where he raised over $1.4 billion in capital and completed several portfolio deals totaling more than $1 billion. Mr. Hughes started his career on Wall Street, initially in investment banking and equity research before transitioning to the buyside, where he managed public and private healthcare investments for Brookside Capital, a hedge fund under the Bain Capital umbrella, and Pyramis Advisors, a Fidelity Investments company. Mr. Hughes currently serves as the executive chairman of Sail Bio and as the chairman of Ikena Oncology. He previously served on the boards of Radius Health (acquired by Gurnet Point Capital) and Translate Bio (acquired by Sanofi). Mr. Hughes earned a B.A. in history from Dartmouth College.

Utpal Koppikar, MBA, has served as a member of our Board of Directors since March 2022. Utpal is currently the Chief Financial Officer of Verily, an Alphabet-backed company focused on precision health. Prior to joining Verily, he served as Executive Vice President and Chief Financial Officer at Atara Biotherapeutics from June 2018 to March 2022, where he oversaw the finance, information technology and investor relations functions and guided the company’s strategy as a member of its senior leadership team. Earlier in his career, Utpal held several senior financial leadership positions at Gilead Sciences (Gilead), including Vice President of Corporate and Operations Finance. During his time there, he led the three-year financial planning process and financial integration of Kite Pharma and played a key role as Gilead’s Vice President of Finance Europe, Middle East and Australia in the launch of multiple HIV and HCV product launches. Before joining Gilead, Utpal served in multiple finance roles of increasing responsibility at Amgen. Utpal previously served as a board member of Flexion Therapeutics Inc. until its sale to Pacira Biosciences in November 2021. He holds an MBA in finance from UCLA’s Anderson School of Management., an M.S. in aeronautical engineering from Stanford University and a B.S. in aerospace engineering from the University of Maryland.